Cjc1295 Dac For Sale

Direct Answer: Sourcing CJC-1295 DAC for Laboratory Research

Sourcing CJC-1295 DAC for sale requires verifying lot-specific purity, synthesis credentials, and analytical documentation. Research-grade CJC-1295 DAC is a synthetic growth-hormone-releasing hormone (GHRH) analog extended with a Drug Affinity Complex to enable covalent binding to serum albumin. High-purity formulations are verified via RP-HPLC and mass spectrometry to guarantee reproducible preclinical results.

When purchasing compounds for laboratory assays, researchers must distinguish between experimental-grade reagents and inferior, unverified materials. At PX1 Research, every batch of CJC-1295 DAC undergoes strict quality assurance protocols, including lot-specific testing in an ISO 17025 accredited laboratory to confirm identity, purity, and sequence integrity before release.

What Is CJC-1295 DAC? Molecular Structure and Design

CJC-1295 DAC (also known as Modified GRF 1-29 with DAC) is a 30-amino-acid tetrasubstituted peptide derivative of endogenous growth hormone-releasing hormone (GHRH). The natural GHRH molecule consists of 44 amino acids, but its biological activity resides primarily within the N-terminal 1-29 sequence. Unmodified GHRH(1-29) amide is subject to rapid enzymatic degradation in plasma, predominantly by dipeptidyl peptidase IV (DPP-IV), resulting in an extremely short biological half-life of approximately 5 to 12 minutes.

To overcome enzymatic cleavage and rapid renal clearance in preclinical models, molecular bioengineers introduced four specific amino acid substitutions at positions 2 (D-Ala), 8 (Gln), 15 (Ala), and 27 (Leu). Furthermore, a maleimido derivative reactive group—known as the Drug Affinity Complex (DAC)—was covalently attached to the lysine residue at the C-terminus via a linker. This DAC moiety enables the peptide to spontaneously and covalently bind to the free cysteine-34 residue of circulating serum albumin upon administration in vivo, dramatically extending its biological half-life to several days.

Preclinical Pharmacokinetics and Mechanism of Action

In animal models and in vitro cellular preparations, CJC-1295 DAC functions as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR) situated on pituitary somatotropes. Receptor activation triggers a intracellular cascade involving adenylate cyclase stimulation, increased cyclic adenosine monophosphate (cAMP) accumulation, and subsequent activation of protein kinase A (PKA). This signal transduction pathway promotes both the transcription and exocytosis of growth hormone (GH).

Preclinical pharmacokinetic studies demonstrate that the albumin-bound CJC-1295 DAC complex remains protected from peptidase activity while maintaining receptor binding capability. Unlike short-acting GHRH mimetics that generate rapid, transient GH spikes, CJC-1295 DAC maintains sustained activation of the GHRH receptor. This continuous stimulation yields prolonged elevations in plasma GH concentrations and drives downstream hepatic synthesis of insulin-like growth factor 1 (IGF-1), making it a valuable tool for tissue repair and metabolic research.

Primary Areas of Preclinical Research

Laboratory investigations using CJC-1295 DAC span several distinct domains of physiological and cellular research. Because the GH/IGF-1 axis plays a central role in protein synthesis, cellular differentiation, and tissue remodeling, investigators utilize this extended GHRH analog to analyze fundamental biological mechanisms:

1. Tissue Repair and Regeneration: Animal studies evaluate how sustained IGF-1 elevation influences collagen deposition, myoblast proliferation, and musculoskeletal recovery following experimental injury models.

2. Metabolic and Adipocyte Research: In vitro and rodent experiments assess the impact of prolonged GHRH receptor stimulation on lipid substrate oxidation, lipolysis rates, and systemic glucose homeostasis.

3. Pituitary Somatotrope Dynamics: Researchers study the receptor desensitization kinetics and intracellular trafficking pathways of GHRHR under continuous exposure to long-acting agonists compared to pulsatile secretagogues.

4. Age-Related Endocrine Changes: Preclinical models of somatopause employ long-acting secretagogues to investigate whether restoring baseline IGF-1 levels alters markers of cellular senescence, bone density, and nitrogen retention.

Comparative Analysis: CJC-1295 DAC vs. Non-DAC and Related GHRH Analogs

Evaluating secretagogue options within the broader spectrum of growth hormone secretagogues requires understanding differences in half-life, receptor signaling dynamics, and structural modifications. The inclusion or exclusion of the Drug Affinity Complex fundamentally alters experimental parameters.

When compared directly, CJC-1295 No DAC (also referred to as Modified GRF 1-29) contains the identical four amino acid substitutions but lacks the C-terminal maleimido linker. Consequently, CJC-1295 No DAC exhibits a half-life of roughly 30 minutes in animal models, producing a discrete, pulsatile release of growth hormone. In contrast, CJC-1295 DAC exhibits a half-life exceeding 6 to 8 days due to irreversible albumin conjugation, maintaining baseline GH and IGF-1 elevations over prolonged observation windows. Earlier baseline analogs such as Sermorelin represent the native 1-29 sequence without non-natural amino acid substitutions or DAC technology, possessing a brief plasma half-life suitable for acute stimulation assays.

Researchers often evaluate GHRH analogs alongside growth hormone secretagogue receptor (GHSR) agonists like Ipamorelin or specialized GHRH derivatives such as Tesamorelin. While GHRH analogs target the pituary GHRH receptor, ghrelin mimetics act via distinct GHSR-1a pathways. Combining these distinct mechanisms in dual-receptor preclinical models allows scientists to observe synergistic somatotrope activation and amplified GH release kinetics.

Laboratory Quality Assurance: HPLC, MS, and Endotoxin Standards

To ensure valid experimental outcomes, research reagents must adhere to stringent purity and stability metrics. Inferior peptide synthesis can introduce truncated sequences, residual organic solvents, trifluoroacetate (TFA) salts, and bacterial lipopolysaccharides (endotoxins) that interfere with cell culture assays or animal physiological responses.

When sourcing CJC-1295 DAC for laboratory studies, researchers should demand independent verification across three critical analytical parameters:

• Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC): Confirms chromatographic purity, ensuring that target peptide content meets or exceeds 99%.

• Electrospray Ionization Mass Spectrometry (ESI-MS): Verifies the exact molecular mass and sequence identity of the tetrasubstituted peptide and attached DAC complex.

• Chromogenic LAL Endotoxin Assay: Quantifies bacterial endotoxin levels to guarantee suitability for sensitive in vitro cell lines and animal models (target < 0.01 EU/μg).

At PX1 Research, lot-specific Certificates of Analysis (COAs) detailing these parameters are publicly accessible for every batch. Explore our analytical methodologies and compound library within the PX1 research library.

Reconstitution Protocols and Lyophilized Storage Conditions

Proper handling and storage preserve the tertiary structure and bioactivity of synthetic peptides. CJC-1295 DAC is supplied as a sterile, lyophilized (freeze-dried) powder packaged in sealed glass vials under inert gas to prevent oxidative degradation during transport.

Upon arrival in the laboratory, unopened vials of lyophilized CJC-1295 DAC should be stored at -20°C for long-term stability (up to 24 months) or 2°C to 8°C for short-term evaluation (up to 90 days). Vials must be protected from ambient light and moisture exposure.

Reconstitution should be conducted using sterile Bacteriostatic Water (0.9% benzyl alcohol) or Sterile Normal Saline under a laminar flow hood. Gently direct the diluent down the glass vial wall rather than directly onto the lyophilized cake. Swirl the vial gently until complete dissolution occurs; never agitate or vortex the solution vigorously, as shear forces can induce peptide aggregation. For precise concentration calculations and volumetric measurements, consult our interactive reconstitution calculator. Reconstituted solutions should be aliquoted into polypropylene microcentrifuge tubes and maintained at 2°C to 8°C for use within 14 to 21 days.

Why Sourcing from PX1 Research Protects Laboratory Integrity

PX1 Research is dedicated exclusively to supporting the scientific community with domestic, high-purity research compounds. We strictly enforce a research-only framework; our products are never sold for human or veterinary administration, medical treatment, or consumer use.

Key operational differentiators at PX1 Research include:

1. USA Manufacturing & Synthesis: All peptides are synthesized in state-of-the-art, GMP-compliant facilities located within the United States.

2. Independent Analytical Verification: Every single lot is tested by an independent ISO 17025 accredited laboratory using RP-HPLC and ESI-MS.

3. Strict Endotoxin Control: Ultra-low endotoxin standards protect the integrity of delicate cell culture systems and animal research protocols.

4. Streamlined Logistics: All orders ship directly from fulfillment centers in California and Arizona, with same-day shipping for orders placed Monday through Friday.

For institutional procurement, high-volume studies, or custom synthesis requirements, laboratory managers can explore dedicated options via our bulk lab accounts portal.